Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 06:33:12 2024-07-18 am EDT			5-day change	1st Jan Change
27.01 ^EUR	+1.23%		+1.37%	-19.70%

Jul. 17	Global markets live: Adidas, TSMC, Vale, HSBC, J&J...
Jul. 17	Bayer: successful trial in prostate cancer	CF

BAYER AG : Goldman Sachs reiterates its Buy rating

January 24, 2020 at 03:08 am EST

Already positive, the research from Goldman Sachs and its analyst Keyur Parekh still consider the stock as a Buy opportunity.. The target price is unchanged at EUR 77.

Latest news about Bayer AG

Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	Jul. 17
Bayer: successful trial in prostate cancer	Jul. 17	CF
BAYER AG : JP Morgan remains Neutral	Jul. 17	ZD
Bayer: new positive data for Nubeqa	Jul. 17	CF
Bayer with trial success in prostate cancer - Analyst: As expected	Jul. 17	DP
BAYER AG : Goldman Sachs sticks Neutral	Jul. 17	ZD
Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial	Jul. 17	MT
Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial	Jul. 17	DJ
Bayer eyes wider Nubeqa use on new prostate cancer trial data	Jul. 17	RE
Bayer seeks approval extension for cancer drug Nubeqa following positive data	Jul. 17	RE
Bayer with trial success in prostate cancer - Larger patient group responsive	Jul. 17	DP
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	Jul. 17	CI
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	Jul. 16	CI
BAYER AG : UBS sticks Neutral	Jul. 15	ZD
European companies cut jobs as economy sputters	Jul. 15	RE
European Midday Briefing : Stocks Extend Rally as U.S. Rate Cut Hopes Deepen	Jul. 12	DJ
BAYER AG : Jefferies gives a Neutral rating	Jul. 12	ZD
Cooling Inflation in Germany, US Boosts DAX Index	Jul. 11	MT
Bayer: FDA Fast Track designation for Parkinson's treatment	Jul. 11	CF
Bayer's Gene Therapy for Parkinson's Gets US Fast Track, UK Innovation Passport Designations	Jul. 11	MT
Fast-track status for gene therapy boosts Bayer	Jul. 11	DP
BASF announces planned closure of two weed killer sites in Germany	Jul. 10	RE
BAYER AG : JP Morgan reaffirms its Neutral rating	Jul. 10	ZD
European companies cut jobs as economy sputters	Jul. 09	RE
BAYER AG : Gets a Neutral rating from Deutsche Bank	Jul. 09	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 02:12 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.68 EUR

Average target price

35.91 EUR

Spread / Average Target

+34.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-19.70%	28.66B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.50%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.34%	247B
NOVARTIS AG	+15.15%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Goldman Sachs reiterates its Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals